Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.
Efforts to further optimize the clinical candidate razaxaban have led to a new series of pyrazole-based factor Xa (fXa) inhibitors. Designed to prevent the potential formation of primary aniline metabolites in vivo, the nitrogen of the carboxamido linker between the pyrazole and proximal phenyl moiety of the razaxaban scaffold was replaced with a methylene group. The resulting ketones demonstrated excellent potency and selectivity for fXa but initially had poor oral bioavailability. Optimization by conversion from a P1 aminobenzisoxazole to a P1 p-methoxyphenyl residue, replacing the 3-trifluoromethylpyrazole with a 3-amidopyrazole, and employing a pyridone P4 group provided a fXa inhibitor with a potency and pharmacokinetic profile equivalent to that of razaxaban and improved selectivity over thrombin.
Bristol-Myers Squibb Research and Development, PO Box 5400, Princeton, NJ 08542-5400, USA.
Jeffrey G
JG
Varnes
Dean A
DA
Wacker
Donald J P
DJ
Pinto
Michael J
MJ
Orwat
Jay P
JP
Theroff
Brian
B
Wells
Robert A
RA
Galemo
Joseph M
JM
Luettgen
Robert M
RM
Knabb
Steven
S
Bai
Kan
K
He
Patrick Y S
PY
Lam
Ruth R
RR
Wexler
D000818:Animals; D018938:Caco-2 Cells; D004285:Dogs; D065427:Factor Xa Inhibitors; D006801:Humans; D011720:Pyrazoles / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D015842:Serine Proteinase Inhibitors / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D015842:Serine Proteinase Inhibitors